- Home
- YGMZ vs IMMX Comparison
YGMZ vs IMMX Comparison
Compare YGMZ & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- IMMX
- Stock Information
- Founded
- YGMZ 2002
- IMMX 2014
- Country
- YGMZ China
- IMMX United States
- Employees
- YGMZ N/A
- IMMX N/A
- Industry
- YGMZ Transportation Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- YGMZ Consumer Discretionary
- IMMX Health Care
- Exchange
- YGMZ Nasdaq
- IMMX Nasdaq
- Market Cap
- YGMZ 72.3M
- IMMX 61.1M
- IPO Year
- YGMZ 2020
- IMMX 2021
- Fundamental
- Price
- YGMZ $1.01
- IMMX $2.71
- Analyst Decision
- YGMZ
- IMMX Strong Buy
- Analyst Count
- YGMZ 0
- IMMX 1
- Target Price
- YGMZ N/A
- IMMX $7.00
- AVG Volume (30 Days)
- YGMZ 144.2K
- IMMX 204.0K
- Earning Date
- YGMZ 01-01-0001
- IMMX 08-11-2025
- Dividend Yield
- YGMZ N/A
- IMMX N/A
- EPS Growth
- YGMZ N/A
- IMMX N/A
- EPS
- YGMZ N/A
- IMMX N/A
- Revenue
- YGMZ $40,429,750.00
- IMMX N/A
- Revenue This Year
- YGMZ N/A
- IMMX N/A
- Revenue Next Year
- YGMZ N/A
- IMMX N/A
- P/E Ratio
- YGMZ N/A
- IMMX N/A
- Revenue Growth
- YGMZ N/A
- IMMX N/A
- 52 Week Low
- YGMZ $0.64
- IMMX $1.26
- 52 Week High
- YGMZ $1.77
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- YGMZ 55.13
- IMMX 53.07
- Support Level
- YGMZ $0.68
- IMMX $2.74
- Resistance Level
- YGMZ $0.87
- IMMX $3.20
- Average True Range (ATR)
- YGMZ 0.07
- IMMX 0.21
- MACD
- YGMZ 0.04
- IMMX -0.01
- Stochastic Oscillator
- YGMZ 89.13
- IMMX 23.44
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. The segments of the company are the trucking business, car owner services business, and liquor distribution business.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.